Repositorio Digital de la UPF
Publication
Artículo científico (JournalArticle)
miRNA signatures associated with vulnerability to food addiction in mice and humans
Food addiction is characterized by a loss of behavioral control over food intake and is associated with obesity and other eating disorders. The mechanisms underlying this behavioral disorder are largely unknown. We aimed to investigate the changes in miRNA expression promoted by food addiction in animals and humans and their involvement in the mechanisms underlying the behavioral hallmarks of this disorder. We found sharp similitudes between miRNA signatures in the medial prefrontal cortex (mPFC) of our animal cohort and circulating miRNA levels in our human cohort, which allowed us to identify several miRNAs of potential interest in the development of this disorder. Tough decoy (TuD) inhibition of miRNA-29c-3p in the mouse mPFC promoted persistence of the response and enhanced vulnerability to developing food addiction, whereas miRNA-665-3p inhibition promoted compulsion-like behavior and also enhanced food addiction vulnerability. In contrast, we found that miRNA-137-3p inhibition in the mPFC did not lead to the development of food addiction. Therefore, miRNA-29c-3p and miRNA-665-3p could be acting as protective factors with regard to food addiction. We believe the elucidation of these epigenetic mechanisms will lead to advances toward identifying innovative biomarkers and possible future interventions for food addiction and related disorders based on the strategies now available to modify miRNA activity and expression., This work was supported by the Spanish “Ministerio de Ciencia e Innovación (MICIN), Agencia Estatal de Investigación (AEI)” (PID2020-120029GB-I00/MICIN/AEI/10.13039/501100011033, RD21/0009/0019, to RM; SAF2015-68341-R, RTI2018-100968-B-100, and PID2021-1277760B-100, to BC; and SAF2017-84060-R-AEI/FEDER-UE, to LD); the “Generalitat de Catalunya, AGAUR” (2017 SGR-669, to RM; 2017 SGR-734, to JMFR; 2017-SGR-738, to BC); the “ICREA-Acadèmia” (2020, to RM, 2021, to BC, and 2022, to JMFR); the “European Commission-DG Research” (PainFact, H2020-SC1-2019-2-RTD-848099, QSPain Relief, H2020-SC1-2019-2-RTD-848068, to RM; CoCA, H2020-667302, and Eat2beNICE, H2020-728018, to BC); the Spanish “Instituto de Salud Carlos III, RETICS-RTA” (RD16/0017/0020, to RM; FIS PI15/01934, PI18/01022, PI21/01361, to JMFR); the Spanish “Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional Sobre Drogas” (PNSD- 2021I076, to RM; PNSD-2019I006, to EMG; PNSD-2017I050, to BC; PNSD-2020I042, to NFC); the “Fundació La Marató-TV3” (2016/20-30, to EMG); the European Regional Development Fund (project no. 01.2.2-LMT-K-718-03-0099) under a grant agreement with the Research Council of Lithuania (LMTLT), to AB; and the Project ThinkGut (EFA345/19), 65% co-financed by the European Regional Development Fund (ERDF) through the Interreg V-A Spain-France-Andorra programme (POCTEFA 2014-2020)